CCP
DGX icon

Corient Capital Partners’s Quest Diagnostics DGX Stock Holding History

Corient Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$361K Hold
2,712
– – 0.03% 414
2022
Q2 		$361K Buy
2,712
+601
+28% +$81.9K 0.03% 427
2022
Q1 		$289K Buy
2,111
+68
+3% +$9.48K 0.02% 553
2021
Q4 		$354K Buy
2,043
+16
+0.8% +$2.43K 0.02% 460
2021
Q3 		$295K Buy
2,027
+164
+9% +$24K 0.02% 496
2021
Q2 		$246K Buy
+1,863
New +$244K 0.02% 556

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Corient Capital Partners's DGX Position: Q3 2022 in Review

Corient Capital Partners held its Quest Diagnostics (DGX) position steady in Q3 2022 at 2,712 shares worth $361K. The position accounts for 0.03% of the portfolio, ranked #414.

Corient Capital Partners first reported a position in DGX in Q2 2021 and has held it in 6 quarters since. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • Corient Capital Partners held 2,712 shares of Quest Diagnostics worth $361K as of Q3 2022.
  • Corient Capital Partners left its Quest Diagnostics share count unchanged in Q3 2022.
  • Quest Diagnostics made up 0.03% of Corient Capital Partners's portfolio in Q3 2022, its #414 holding.
  • Corient Capital Partners first reported a position in Quest Diagnostics in Q2 2021 and has held it in 6 quarters since.
  • 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.